KUALA LUMPUR, Nov 18 (Bernama) -- SELLAS Life Sciences Group Inc (SELLAS), a late-stage clinical biopharmaceutical company, has announced positive topline results from the pivotal randomised Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukaemia (AML).